Business context and reporting period
Filing identity: The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024—not a Crescent BioPharma, Inc. filing. Verify the company and filing before relying on this summary.
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates for cancer and inflammatory diseases. It has no approved products and reported no product-sales revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None reported | No revenue reported in the presented operating results |
| Research and development expense | $6.03 million | $5.42 million; up 11% |
| General and administrative expense | $5.09 million | $5.52 million; down 8% |
| Total operating expenses / operating loss | $11.12 million | $10.94 million |
| Interest income | $0.38 million | $0.58 million |
| Net loss | $10.74 million | $10.36 million; loss increased about 4% |
| Net loss per share, basic and diluted | $0.17 | $0.17 |
| Net cash used in operations | $10.51 million | $11.61 million |
Gross margin is not meaningful because the company reported no revenue. Cash and cash equivalents were $31.28 million at March 31, down from $41.79 million at December 31, 2023. Total assets were $34.20 million; total liabilities were $5.29 million, principally current liabilities and lease obligations. No borrowings are reported. The remaining lease liability was $0.63 million. Stockholders’ equity was $28.91 million, and accumulated deficit was $467.22 million.
Material changes, outlook, and risks
- R&D expense rose mainly because of uproleselan manufacturing and formulation costs, while G&A declined largely due to a prior-year severance accrual and lower professional fees. Lower invested cash balances reduced interest income.
- Management estimated existing cash would fund operations through Q4 2024, excluding potential financing or business-development proceeds, and planned expense reductions. The filing states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. The company had no committed external funding source; approximately $66.0 million remained available under its at-the-market sales agreement, subject to conditions.
- Subsequent event: On May 6, 2024, the company announced that its Phase 3 uproleselan trial in relapsed/refractory AML did not achieve statistically significant improvement in overall survival in the intent-to-treat population. Median overall survival was 13 months with uproleselan versus 12.3 months with placebo. The company said it was evaluating the data with medical, statistical, and regulatory experts.
- In April 2024, the company committed $3.77 million for raw materials supporting uproleselan manufacturing and paid a non-refundable $1.13 million advance; the remainder is due upon completion of the produced quantity.
- Other pipeline programs include GMI-1687, which completed a Phase 1a healthy-volunteer trial in December 2023, and earlier-stage programs. The company also disclosed an ongoing NCI-sponsored uproleselan study and a Phase 3 bridging study in Greater China conducted by Apollomics.
Important facts for investors to verify
- Confirm that this GlycoMimetics filing—not a Crescent BioPharma filing—is the intended source.
- Review the full Phase 3 uproleselan results, including statistical analyses and any subsequent regulatory or development decisions.
- Assess financing needs and cash runway after the trial outcome, planned expense reductions, and any equity issuance under the ATM facility.
- Check progress and potential funding implications of the NCI and Apollomics trials, and the conditions attached to potential milestones or royalties.
- Review the manufacturing commitment and other future development costs against available liquidity.